Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

876
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
876
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

263
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
263
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

693
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
693
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

808
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
808
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

750
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dogs with intrahepatic portal hypertension of congenital cause have distinct diagnostic findings compared to dogs with chronic hepatitis-related portal hypertension.

Journal of the American Veterinary Medical Association·2026
Same author

Clinical Guidelines for Fecal Microbiota Transplantation in Companion Animals.

Advances in small animal care·2026
Same author

Subclinical Canine Chronic Enteropathy: Early Detection and Prevention is the Key to Cure.

The Veterinary clinics of North America. Small animal practice·2026
Same author

A Paradigm Shift in Gastrointestinal Disease.

The Veterinary clinics of North America. Small animal practice·2026
Same author

Supplement use is common in Dog Aging Project participants, especially among dogs with orthopedic conditions, and varies by life stage.

American journal of veterinary research·2025
Same author

Orally administered cholestyramine increases fecal bile acid excretion in healthy dogs.

American journal of veterinary research·2025

Related Experiment Video

Updated: Dec 2, 2025

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy
04:05

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy

Published on: August 22, 2025

439

Gastroprotective Therapy.

M Katherine Tolbert1

  • 1Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M College of Veterinary, 4474 TAMU | College Station, TX 77843-4474, USA.

The Veterinary Clinics of North America. Small Animal Practice
|November 2, 2020
PubMed
Summary

Proton pump inhibitors are effective for upper gastrointestinal injury but not all causes. Choosing the right gastroprotective drug depends on the injury

Keywords:
Acid suppressantGastric ulcerHistamine-2 receptor antagonistProton pump inhibitor

More Related Videos

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.5K

Related Experiment Videos

Last Updated: Dec 2, 2025

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy
04:05

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy

Published on: August 22, 2025

439
Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.5K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Gastroesophageal mucosal injury is treated with various drugs.
  • Acid suppressants, coating agents, prostaglandin analogs, and antacids are available.
  • Proton pump inhibitors (PPIs) are highly effective for upper gastrointestinal injury.

Purpose of the Study:

  • To review the efficacy of different gastroprotective agents.
  • To highlight the role of PPIs in managing upper gastrointestinal injury.
  • To guide the selection of appropriate gastroprotective therapy.

Main Methods:

  • Literature review of gastroprotective drug classes.
  • Analysis of treatment efficacy for esophagitis and gastroduodenal injury.
  • Evaluation of factors influencing drug choice.

Main Results:

  • Proton pump inhibitors demonstrate superior efficacy in treating upper gastrointestinal injury.
  • No single agent is effective for all etiologies of gastrointestinal injury.
  • Adverse effects and injury characteristics influence therapeutic decisions.

Conclusions:

  • Proton pump inhibitors are the most effective medical treatment for many upper gastrointestinal injuries.
  • Therapeutic decisions require consideration of the specific cause and location of injury.
  • Individualized treatment plans are essential for optimal gastroprotection.